CALCIUM CHLORIDE INJECTION [MEDICAL PURCHASING SOLUTIONS, LLC]

CALCIUM CHLORIDE INJECTION [MEDICAL PURCHASING SOLUTIONS, LLC]
PDF | XML

NDC 71872-7044-1
Set ID 6b15706b-199c-beba-e053-2991aa0a1734
Category HUMAN PRESCRIPTION DRUG LABEL
Packager Medical Purchasing Solutions, LLC
Generic Name
Product Class
Product Number
Application Number
  • SPL UNCLASSIFIED SECTION

    CALCIUM CHLORIDE
    INJECTION, USP, 10%

    13.6 mEq (1 g) per 10 mL
    100 mg (1.36 mEq)/ mL
    Osmolarity approximately 2050 mOsmol/L

  • DESCRIPTION

    Calcium Chloride Injection, USP, 10%, is a sterile aqueous solution containing, in each mL, 100 mg (1.36 mEq) calcium chloride. The pH of the solution may have been adjusted with hydrochloric acid and / or calcium hydroxide, when necessary. The air above the liquid in the individual containers has been displaced by flushing with nitrogen during the filling operation. The preparation contains no antimicrobial preservatives and is intended as a single-dose vial; once the unit is assembled and used, any remaining portion of the solution must be discarded with the entire unit.

    Calcium Chloride, USP, contains two molecules of water of hydration and is chemically designated as CaCl 2 • 2H 20.

  • CLINICAL PHARMACOLOGY

    Calcium is the fifth most abundant element in the body, the major fraction of which is found in the bony structure. Calcium plays important physiological roles; it is essential for the functional integrity of the nervous and muscular systems; it is necessary for normal cardiac function; and it is one of the factors involved in the mechanism of blood coagulation.

  • INDICATIONS AND USAGE

    Calcium Chloride Injection, USP, 10% is indicated:

    In the treatment of hypocalcemia in conditions requiring a prompt increase in plasma calcium levels (e.g., neonatal tetany and tetany due to parathyroid deficiency, vitamin D deficiency and alkalosis) and for prevention of hypocalcemia during exchange transfusions.

    As adjunctive therapy in the management of acute symptoms in lead colic.

    In the treatment of magnesium intoxication due to overdosage of magnesium sulfate.

    In severe hyperkalemia, to combat deleterious effects on electrocardiographic (ECG) function, pending correction of the potassium level in the extracellular fluid.

    In cardiac resuscitation, particularly after open heart surgery, when epinephrine fails to improve weak or ineffective myocardial contractions.

  • CONTRAINDICATIONS

    Calcium chloride is contraindicated for cardiac resuscitation in the presence of ventricular fibrillation.

  • WARNINGS

    Calcium chloride should be injected into a large vein very slowly, as it may cause peripheral vasodilatation and a cutaneous burning sensation. A moderate fall in blood pressure due to vasodilatation may attend the injection. Since calcium chloride is an acidifying salt, it is usually undesirable in the treatment of hypocalcemia or renal insufficiency.

  • PRECAUTIONS

    General

    Calcium Chloride Injection, USP, 10% is irritating to veins and must not be injected into tissues, since severe necrosis and sloughing may occur. Great care should be taken to avoid extravasation or accidental injection into perivascular tissues.

    Solutions should be warmed to body temperature. Injections should be made slowly through a small needle into a large vein to minimize venous irritation and avoid undesirable reactions. It is particularly important to prevent a high concentration of calcium from reaching the heart because of the danger of cardiac syncope. If injected into the ventricular cavity in cardiac resuscitation care must be taken to avoid injection into the myocardial tissue.

    Drug Interactions

    Because of the danger involved in the simultaneous use of calcium salts and drugs of the digitalis group, a digitalized patient should not receive an intravenous injection of a calcium compound unless the indications are clearly defined.

    Calcium salts should not generally be mixed with carbonates, phosphates, sulfates or tartrates in parenteral admixtures.

    ADVERSE REACTIONS

    Rapid I.V. injection may cause the patient to complain of tingling sensations, a calcium taste, a sense of oppression or “heat wave.”

    Injections of calcium chloride are accompanied by peripheral vasodilation as well as a local “burning” sensation, and there may be a moderate fall in blood pressure.

    DOSAGE AND ADMINISTRATION
    FOR INTRACARDIAC OR INTRAVENOUS USE ONLY

    INJECT SLOWLY
    Calcium Chloride Injection, USP, 10%, is administered only by slow intravenous injection (not to exceed 1 mL/min) and / or in cardiac resuscitation, by injection into the ventricular cavity. It must not be injected into the myocardium.

    The usual precautions for intravenous therapy should be observed. If time permits, the solution should be warmed to body temperature. The injection should be halted if the patient complains of any discomfort; it may be resumed when symptoms disappear. Following injection, the patient should remain recumbent for a short time.

    INTRACARDIAC USE
    For cardiac resuscitation, inject into the ventricular cavity, not into the heart muscle.

    Usual Adult Dosage: 200 to 800 mg (2 to 8 mL) when injected into the ventricular cavity.

    Pediatric Dosage: 0.2 mL/kg of body weight.

    INTRAVENOUS USE
    Hypocalcemic Disorders

    Usual Adult Dosage: 500 mg to 1 g (5 to 10 mL) at intervals of 1 to 3 days, depending on the response of the patient and / or results of serum calcium determinations. Repeated injections may be required because of rapid excretion of calcium.

    Pediatric Dosage: 0.2 mL /kg of body weight. Maximum 1-10 mL/day.

    Magnesium Intoxication
    Initial Adult Dose: 500 mg (5 mL) administered promptly and the patient observed for signs of recovery before further doses are given.

    Hyperkalemic ECG Disturbances of Cardiac Function
    Dosage should be adjusted by constant monitoring of ECG changes during administration.

  • HOW SUPPLIED

    CALCIUM CHLORIDE INJECTION, USP, 10%

    In unit-use packages containing a Luer-Jet™ Luer-Lock Prefilled Syringe.

    Stock No. 3304      NDC 76329-3304-1      10 mL

    Ten cartons per package.

    Syringe Assembly Directions:
    USE ASEPTIC TECHNIQUE
    Do not assemble until ready to use.

    Instructions

    *CAUTION: IMPROPER ENGAGING MAY CAUSE GLASS BREAKAGE AND SUBSEQUENT INJURY.

    Store at controlled room temperature 15° to 30°C (59° to 86°F).

    Rx Only

    INTERNATIONAL MEDICATION SYSTEMS, LIMITEDSo. El Monte, CA 91733, U.S.A.                                         Rev. 2-13
    An Amphastar Pharmaceuticals Company

    © INTERNATIONAL MEDICATION SYSTEMS, LIMITED 2013

  • PRINCIPLE DISPLAY PANEL: Syringe Label

    Osmolarity approx. 2050 mOsmol per liter (calc.)

    FOR SLOW INTRAVENOUS USE ONLY

    SEE INSERT / SINGLE DOSE

    NO PRESERVATIVE ADDED

    IMS, LIMITED

    Rx Only

    So. El Monte, CA 91733, U.S.A.

    7633040B 8-11

    10 mL      1 g (13.6 mEq)       100 mg / mL

    CALCIUM CHLORIDE INJ., USP, 10%

    Approx. mL  0   1   2   3   4   5   6   7   8   9

    Label

  • PRINCIPLE DISPLAY PANEL: Carton

    Luer-Lock Prefilled Syringe

    Rx only

    NDC 76329-3304-1

    STOCK NO. 3304

    CALCIUM CHLORIDE INJ. USP, 10%

    1.36 mEq/ mL (100 mg/ mL)

    13.6 mEq (1 g) per 10 mL

    One 10 mL Single Dose Prefilled Syringe

    Single use, do not reuse or resterilize.

    FOR SLOW INTRAVENOUS USE

    LUER-JET TM LUER-LOCK PREFILLED SYRINGE

    Carton

  • PRINCIPAL DISPLAY PANEL: Outer package label

    NDC 71872-7044-1

    1 - Prefilled Syringe

    Calcium Chloride Inj. USP, 10%

    Rx Only

    PDP

  • INGREDIENTS AND APPEARANCE
    CALCIUM CHLORIDE 
    calcium chloride injection
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:71872-7044(NDC:76329-3304)
    Route of AdministrationINTRAVENOUS, INTRAVENTRICULAR
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    CALCIUM CHLORIDE (UNII: M4I0D6VV5M) (CALCIUM CATION - UNII:2M83C4R6ZB) CALCIUM CHLORIDE100 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    CALCIUM HYDROXIDE (UNII: PF5DZW74VN)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:71872-7044-11 in 1 BAG03/15/2018
    11 in 1 CARTON
    110 mL in 1 SYRINGE; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    unapproved drug other05/01/1973
    Labeler - Medical Purchasing Solutions, LLC (601458529)
    Establishment
    NameAddressID/FEIBusiness Operations
    Medical Purchasing Solutions, LLC601458529repack(71872-7044)

Related Drugs